Cite
Goebeler M, Bata-Csörgő Z, De Simone C, et al. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2021;doi: 10.1111/bjd.20782.
Goebeler, M., Bata-Csörgő, Z., De Simone, C., Didona, B., Remenyik, E., Reznichenko, N., Stoevesandt, J., Ward, E. S., Parys, W., de Haard, H., Dupuy, P., Verheesen, P., Schmidt, E., Joly, P. (2021). Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. The British journal of dermatology, . https://doi.org/10.1111/bjd.20782
Goebeler, M, et al. "Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial." The British journal of dermatology vol. (2021). doi: https://doi.org/10.1111/bjd.20782
Goebeler M, Bata-Csörgő Z, De Simone C, Didona B, Remenyik E, Reznichenko N, Stoevesandt J, Ward ES, Parys W, de Haard H, Dupuy P, Verheesen P, Schmidt E, Joly P. Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial. Br J Dermatol. 2021 Oct 05; doi: 10.1111/bjd.20782. Epub 2021 Oct 05. PMID: 34608631.
Copy
Download .nbib